Argos Therapeutics has raised about $45 million in its IPO after having priced its offering of 5.625 million shares at $8 per share. The stock began trading Friday on the NASDAQ under the ticker symbol "ARGS." Piper Jaffray & Co, Stifel, Nicolaus & Company and JMP Securities served as lead underwriters. Based in Durham, NC, Argos is a developer of immunotherapies that treat cancer and infectious diseases. Its backers include Forbio Capital Partners, TVM Capital, Lumira Capital, Intersouth Partners, Morningside Group, Green Cross Corp. and Aurora Funds.